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Abstract
Background: Intention-to-treat (ITT) analysis is commonly recommended for use, due to its benefits on external
validity, in randomized, controlled trials (RCTs). No published reports describe how ITT analysis, as well as alternative
approaches, are used in anti-infective RCTs. The purpose of this study is to describe the extent to which ITT analysis and
alternative data approaches are used, the practices used to handle missing subject data, and whether non-inferiority
trials present both ITT and per protocol (PP) analyses. Results of this analysis will help guide end users of infectious
diseases primary drug literature.
Methods: A cross-sectional study of RCTs of anti-infectives published from January 1, 2013 through December 31, 2014
was conducted. A PubMed search identified relevant articles published in five specialty infectious diseases journals and
four general medical journals. Each article was reviewed by two independent investigators with discrepancies resolved
by consensus. Descriptive statistics were used to quantify results.
Results: One hundred four articles met study criteria. The most common medication classes represented in the RCTs
were hepatitis C antivirals (26 %), antibacterials (25 %), and antiretrovirals (21 %). Thirty studies (29 %) were non-
inferiority trials. Most studies (77 %) described use of ITT or modified ITT (mITT) in their methods. Of the ITT and mITT
studies, most (73 %) did not describe practices used to handle missing data. Most (97 %) non-inferiority trials described
use of ITT, mITT, or both; however, only 15 (50 %) also described use of PP.
Conclusions: RCTs of anti-infectives commonly employ ITT and mITT. Most do not describe how missing data were
addressed. Non-inferiority trials of anti-infectives do not consistently employ both ITT and PP populations.
Keywords: Intention-to-treat, Per protocol, Anti-infectives, Clinical trial evaluation
Abbreviations: AHFS, American Hospital Formulary Service; BCOF, Best observation carried forward; CONSORT, The
Consolidated Standards of Reporting Trials; EMA, European Medicines Agency; ENT, Ear, nose, and throat;
IRB, Institutional review board; ITT, Intention-to-treat; LOCF, Last observation carried forward; MeSH, Medical Subject
Heading; mITT, Modified intention-to-treat; PP, Per protocol; RCT, Randomized, controlled trial
Background
As consumers of primary literature, medical professionals
must become proficient in interpreting and evaluating
published studies in order to determine applicability of
results toward solving patient care problems. Similarly,
investigators face many critical decisions when designing
and conducting randomized, controlled trials (RCTs). One
such decision is determining which study population to
analyze. The three most commonly analyzed populations
in RCTs are intention-to-treat (ITT), modified ITT
(mITT), and per protocol (PP) [1, 2]. See Table 1 for defi-
nitions of these populations.
Analysis using ITT is generally preferred, and most
often used, by RCTs [1, 2]. ITT analysis includes all
patients regardless of adherence to study protocol and
attrition, maximizing external validity, and more closely
mirroring circumstances encountered in actual practice.
This yields estimates of treatment effect that are more
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conservative compared to a PP analysis, and decreases
risk for Type I statistical error [3, 13]. This approach
also allows authors to preserve sample size [1–3]. How-
ever, a true ITT may include patients who have never
received any study medication, regardless of treatment
arm, which could be problematic, especially when evalu-
ating non-inferiority. A mITT analysis may be preferred
by investigators in order to balance the improved exter-
nal validity obtained with ITT with the improved
internal validity (i.e., assurance that study results accur-
ately reflect the experiences of study subjects) associated
with PP. For example, a mITT that only includes
patients who received at least one dose of study medica-
tion is often employed in assessing differences in adverse
drug events between treatment groups because it could
be considered inappropriate to attribute an adverse drug
event to a medication never received by the patient.
Additional qualifiers such as the “microbiological” mITT,
are sometimes added in the case of infectious diseases
literature. Depending of the specific interventions and
clinical outcomes being measured, an analysis of this
depth may or may not be pertinent to assessment of the
study’s impact on clinical decision making.
By including all patients regardless of violations or at-
trition, ITT tends to make the two treatment groups
more similar [7]. For this reason, it has been proposed
to be less appropriate in non-inferiority trials, where the
goal of the investigation is to establish whether the inter-
vention is “just as good” as the standard of care. In a
non-inferiority trial, the null hypothesis is that the
intervention is inferior to the standard, and an ITT
population may be less conservative [4]. However, if an
intervention is to be managed within a hospital where
violations may be low due to improved adherence, ITT
and PP findings should be similar. Regardless, both ITT
and PP are recommended for presentation of results of
non-inferiority trials, and the reader should be directed
toward the more conservative findings.
When ITT and mITT are used, investigators must de-
termine how to account for missing data due to attrition.
Common approaches include using the last observation
carried forward (LOCF) or assuming treatment failure
when data are missing [2, 4]. The most ideal or preferred
method has not been established, and investigators
should consider conducting sensitivity analysis to inves-
tigate potential differences among methods. Regardless
of which method is used, authors should describe the
details of how they accounted for missing outcome data,
as the approach taken could have substantial impact on
the estimated effect size determined in the study.
CONSORT, the Consolidated Standards of Reporting
Trials, provides standards for reporting clinical trials [1].
The CONSORT 2010 Statement recommends that
authors who are reporting on clinical trials include “a clear
description of exactly who was included in each analysis”
regardless of which population is used. It is important for
authors to provide details about which patients are
included in the analysis so that readers have the informa-
tion they need to interpret the results of the study.
Furthermore it is important that the reported study popu-
lations in the methods section of the manuscript are con-
sistent with what is utilized in the results and discussion
section of the document. Failure to do so may lead to a
misrepresentation of the true outcomes of a study.
Few previous studies describe whether published RCTs
are meeting the CONSORT recommendation of clearly
defining the population that was analyzed; however,
available studies suggest significant gaps, particularly in
describing how missing data are handled [5, 6]. In the
absence of consistently applied principles, medical pro-
fessionals are left to compare trials of similar drugs
under potentially very different conditions. Similar data
have not yet been described in a sample of RCTs of anti-
infectives, a group of studies associated with high
dropout rates, small sample size, and a high rate of non-
inferiority trials [7]. Each of these issues could pose
challenges related to use of ITT, mITT, and PP analyses.
In order to better understand use of ITT and related
methods in published RCTs of anti-infectives, and how
current practice benchmarks to best practices, the objec-
tives of this study were to:
1. Describe the extent to which ITT analysis and
alternative approaches to data analysis are used.
2. Describe practices used to handle missing data due
to attrition.
3. Determine whether non-inferiority trials present
both ITT and PP analyses.
Methods
This was a cross-sectional study of RCTs of anti-
infectives published from January 1, 2013 through
December 31, 2014. Investigators conducted a prelimin-
ary literature search that identified a two-year search
Table 1 Definitions of Data Analysis Populationsa
Population Definitionc
ITT All randomized patients are analyzed, regardless of whether
each patient completed the trial, or even took a dose of
study medication.b
mITT All patients randomized patients are analyzed, if they fit a
predefined modification to the ITT population. A common
modification is including all patients who were randomized
and also received at least one treatment dose.
PP Only the patients who completed treatment according to
the planned protocol are analyzed.
aITT intention-to-treat, mITT modified ITT, PP per protocol
bITT may also be defined with the added caveat that there are no missing
measurements; however, this standard was not applied in this investigation
c[2]
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timeframe would likely identify approximately 100 RCTs
meeting study criteria. A goal anticipated sample of 100
RCTs was selected based on prior similar studies [6, 8].
In order to be included, RCTs had to be published in one
of nine medical journals: five specialty infectious diseases
journals (i.e., Antimicrobial Agents and Chemotherapy,
Clinical Infectious Diseases, Journal of Antimicrobial
Chemotherapy, Journal of Infectious Diseases, Lancet Infec-
tious Diseases) and four general medicine journals known
to publish impactful RCTs of anti-infectives (i.e., British
Medical Journal, Journal of the American Medical Associ-
ation, Lancet, and New England Journal of Medicine).
These journals were selected based on a prior study sug-
gesting that they typically publish the most impactful RCTs
of anti-infectives; they also represent the highest impact
journals in their respective disciplines [9]. Impact factors
ranged from 4.476 (Antimicrobial Agents and Chemother-
apy) to 21.372 (Lancet Infectious Diseases) for infectious
diseases journals and 17.445 (British Medical Journal) to
59.558 (New England Journal of Medicine) for general
medicine journals [10–13]. RCTs that had a non-efficacy
primary endpoint, studied efficacy of vaccinations, or were
designed as a crossover trial were excluded, due to the
potential for confounding variables that could disrupt an
assessment of data analysis populations.
A PubMed search was used to identify relevant articles
published in the nine selected journals. The search used
the Medical Subject Heading (MeSH) term “anti-infect-
ive agents,” and was filtered to only yield RCTs pub-
lished in the study timeframe. Search results (abstracts
and articles, as necessary) were manually reviewed to
exclude articles that were not RCTs of anti-infectives, as
well as articles that met exclusion criteria.
Data from each article were extracted by two inde-
pendently acting study investigators, with all investiga-
tors participating. Discrepancies were resolved by
consensus under consultation with a third independent
investigator. In order to build consistency among the
four investigators, data collection was piloted for three
articles that met study criteria, but were published prior
to 2013. The following data were extracted in order to
describe the sample of RCTs: journal of publication,
intervention, medication class using the American
Hospital Formulary Service (AHFS) classification of the
intervention, indication for treatment, blinding, number
of treatment arms, number of randomized patients,
primary endpoint, and primary endpoint classification
(i.e., continuous, ordinal, nominal). It was decided not to
measure inter-rater reliability, since investigators
extracted objective data only, without judging, interpret-
ing, measuring, scoring, or rating its merits. Published
recommendations suggest inter-rater reliability would be
needed to assess consistency in the latter, but not the
former, scenario [14].
Data gathered to address study objectives were collected
in the same manner as described above. For each article,
the primary data analysis approach (e.g., ITT, mITT, PP)
described in the methods and used to present results was
determined. It was identified during the data collection
pilot that, on occasion, the primary data analysis approach
in the methods differed from what was actually used in re-
sults, hence the decision to extract both data points. If
clinical trial authors incorrectly classified an approach
(e.g., stated that an article was ITT, when it had actually
been modified in some way, such as requiring patients to
receive at least one dose to be included in analysis), it was
re-classified using the correct definition. Additionally, the
total number and type(s) of data analysis approaches
appearing in the article results were counted. Similarly, the
primary approach used to handle missing data (e.g., LOCF)
described in methods, and the number and type(s) of
approaches to missing data present in the results were
determined. Finally, each study was classified as a non-
inferiority trial if non-inferiority methods were used to
evaluate the primary endpoint, and as having favorable or
unfavorable results according to whether the study was a
superiority (i.e., improved efficacy compared to control) or
non-inferiority (i.e., efficacy no worse than control) design.
Descriptive statistics using Microsoft Excel® were used
to present article demographic information, as well as to
address objectives 1, 2, and 3. Median and interquartile
range were used to describe results for ordinal and non-
parametric continuous data. Number and percentage
were used to describe nominal data. The study was
determined to be exempt from institutional review board
(IRB) review upon consultation with a local IRB
representative.
Results
The initial literature search identified 185 articles, 81
(44 %) of which failed to satisfy study criteria (see Fig. 1).
The most common reasons for removal were a non-
anti-infective intervention (n = 35), having a primary
endpoint that was not a measure of efficacy (n = 18), and
not an RCT (n = 17).
The initial literature search identified 104 articles (56 %)
that satisfied study criteria and were included in the ana-
lysis. See the Additional file 1 for citations of the final
sample of studies. The most common medication classes
represented were hepatitis C antivirals (n = 27, 26 %), anti-
bacterials (n = 26, 25 %), and antiretrovirals (n = 22, 21 %).
Most studies contained 2 (n = 64, 62 %) or 3 (n = 23, 22 %)
treatment groups. Thirty studies (29 %) were non-
inferiority trials; all others were superiority. Fifty percent
(n = 52) of studies were double-blind and 46 % (n = 48)
were open-label. Sixty-eight percent (n = 71) of studies
used a nominal or dichotomous primary endpoint
(e.g., clinical cure, microbiological cure, whether a
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patient met a target viral load), and 31 % (n = 32) used
a continuous primary endpoint (e.g., mean viral load,
time to event). Seventy-six percent (n = 79) had favor-
able results. See Table 2 for a full overview of descrip-
tive results.
Of the included studies (n = 104), most studies
described use of ITT or mITT as their primary approach
to data analysis in their methods (n = 80, 77 %) and sub-
sequently used one of these approaches as the primary
data analysis approach in their results (n = 85, 82 %).
Forty-one percent (n = 43) of studies used multiple data
analysis approaches. No studies described use of data
analysis approaches other than ITT, mITT, or PP. See
Table 3 for a further overview of related results.
For studies that used mITT as a primary or secondary
approach to data analysis (n = 53), the most common
modification was to assess all patients who received at
least one dose of study drug (n = 24, 45 %). An
additional 13 studies (25 %) included patients who re-
ceived at least one dose of study drug and also satisfied
one additional criterion (e.g., no resistance at baseline,
present for at least one follow up, no violations of good
clinical practice). Less common modifications included
lack of microbiologically confirmed infection (n = 3),
coinfection (n = 2), lack of primary outcome data (n = 2),
and discontinuation for other reason (n = 1). Modifica-
tions were not indicated in 8 studies (15 %).
Of the 96 studies that used ITT, mITT, or both, most
(n = 70, 73 %) did not describe practices used to handle
missing data due to dropouts. One study did not indi-
cate planned modifications, but did state that no patients
had missing data. The described practices included as-
suming treatment failure (n = 13, 14 %), best observation
carried forward (BOCF) (n = 3, 3 %), LOCF (n = 3, 3 %),
excluding missing data from the analysis (n = 3, 3 %),
and use of other single or multiple imputation methods
(n = 3, 3 %).
Table 2 Descriptive Information from Sample RCTs (N = 104)a
Medication class, no. (%) Results






Miscellaneous antivirals 4 (4)
Neuraminidase inhibitors 4 (4)
Antihelminthics 2 (2)
Antiprotozoals 2 (2)
Nucleosides and nucleotides 2 (2)
Monoclonal antibodies 1 (1)








Study design, no. (%)
Superiority 74 (71)
Non-inferiority 30 (29)





Not described 3 (3)
Endpoint type, no. (%)
Nominal 71 (68)
Continuous 32 (31)
Unable to determine 1 (1)









Non-anti-infective intervention (n = 35)
Primary endpoint that was not a measure 
of efficacy (n = 18)
Not an RCT (n = 17)
Cross-over study design (n = 6)
Post-hoc analysis of RCT (n = 5)
Fig. 1 Articles Screened. Describes the number of articles screened
in the initial literature search, as well as the reasons for article
exclusion. RCT: Randomized, controlled trial
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Twenty-nine of the 30 non-inferiority trials (97 %)
described use of ITT (n = 10, 33 %), mITT (n = 16, 53 %),
or both (n = 3, 10 %) in the study methods. The remaining
study described use of mITT in the study results, but not
in the the study methods. However, only 15 (50 %) also
described use of PP. Consistent with overall results, the
approach used to account for missing data due to attrition
was only described in 8 studies (27 %).
Discussion
Results from this study strongly suggest that most RCTs
of anti-infectives consistently employ ITT or mITT,
which should provide the most conservative estimate of
effect size (with the possible exception of non-inferiority
trials). Few studies (4 %) described PP as their primary
approach. This is in harmony with current best practices
and recommendations for appropriate conduction of
RCTs, recommending a multi-faceted approach to data
analysis that centers on use of ITT [4]. This is also an
improvement compared to previous evaluations of
musculoskeletal and ear, nose, and throat (ENT) RCTs,
where fewer studies (68 % and 12 %, respectively) used
ITT or mITT as the primary data analysis population
[6, 8]. While use of ITT is not specifically recom-
mended in CONSORT, the relatively consistent use of
ITT and mITT supports CONSORT Item 13, which
advocate for clarity in describing the numbers of
patients analyzed for each outcome, and providing rea-
sons for patient exclusions [1].
Although the overall results regarding use of ITT in
this sample of clinical trials were positive, a substantial
minority of studies (17 %) failed to clearly define their
primary population of analysis as recommended in
CONSORT [1]. This failure decreases study transpar-
ency and puts the onus on the reader to determine
whether an appropriate population was used when inter-
preting results. Misinterpretation of study group size
may cause significant ramifications to study applicability,
particularly in subspecialties such as infectious diseases
where sample size might be lower than ideal. Addition-
ally, considerable inconsistency between the primary
population defined in methods and the one in used to
illustrate results was anecdotally observed. These types
of discrepancies can be particularly concerning when
ITT is described in the methods, but less conservative
mITT, or even PP, analyses are described in the study re-
sults. This could contribute to systematic overestimation
of observed effect size of anti-infectives.
The most common modification used in mITT analyses
required analyzed patients to receive at least one dose of
medication (48 %). This minor modification would not be
expected to greatly alter the observed effect size compared
to ITT, and the finding is similar to a previous study
where this was the most common modification (56 %)
[15]. From a clinician’s perspective, a mITT population,
depending on the modification, may provide a more rep-
resentative picture of actual clinical practice. Practically
though, increasing the number of modifications can intro-
duce bias in the form of changing the overall study into a
per-protocol analysis. Study authors and readers alike
must balance these competing interests when designing
and reading this type of manuscript. To the authors’
knowledge, there is no standard recommendation for the
number or types of modifications considered appropriate
for a mITT analysis. On a related note, it was observed
that mITT was frequently miscategorized as ITT, which
could be misleading to the reader depending on the de-
gree of modification. This underscores previously reported
findings that as few as 42 % of published RCTs claiming to
use ITT actually assessed all randomized patients in their
primary analysis [5].
A problem with ITT trials that is somewhat unique to
infectious diseases research is the issue of how to account
for patients who are randomized to a treatment group,
but never positively have an established infection. Their
inclusion into the study population while true to an ITT
model provides increased noise, with limited benefit in
terms of determining the overall effectiveness of an inter-
vention. Simply excluding this population can also be
viewed in a different light as a deviation from standard
practice and less “real-world” in extrapolation. Our results
suggest that microbiological confirmation of infectious is
less commonly used as a mITT modification.
Table 3 Data Analysis Methods in Sample RCTs (N = 104)a
Primary approach described in methods, no. (%) Results
mITT 42 (40)
ITT 38 (37)
Not stated or unclear 17 (16)
PP 4 (4)
Both mITT and PP 2 (2)
Both ITT and PP 1 (1)




Primary approach used in results, no. (%)
mITT 51 (49)
ITT 34 (33)
Not stated or unclear 10 (10)
PP 5 (5)
Both mITT and PP 2 (2)
Both ITT and PP 2 (2)
aITT intention-to-treat, mITT mITT, PP per protocol
bNot exclusive
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The overwhelming majority of RCTs that used ITT or
mITT did not describe how investigators accounted for
missing patient data due to missed visits or dropouts.
These results were worse than prior studies where this
information was provided in 58 to 65 % of RCTs [6, 16].
To the investigators’ knowledge, there is no current,
rigorous standard regarding an ideal approach to this
practice. The European Medicines Agency (EMA) has
acknowledged lack of consensus in this area and sug-
gests preferential use of more conservative approaches
to handling missing data [17]. Some commonly used ap-
proaches to missing data (e.g., best observation carried
forward [BCOF], LCOF) could easily result in a more
“best case” result that might not truly reflect patient out-
comes [4]. Other approaches, such as assuming treat-
ment failure may be preferable as they would result in a
more conservative estimation of effect size, especially in
subspecialties such as infectious diseases, where dichot-
omous clinical endpoints (70 % in this study) are
commonly employed [4, 17, 18]. Guidelines from EMA
suggest assuming treatment failure may be most appro-
priate for clinical trials investigating response-type of
endpoints, which comprised the majority in this study
[17]. A positive finding was that the most commonly de-
scribed approach was assuming treatment failure (13 %).
ITT or mITT was employed in the majority (97 %) of
non-inferiority trials. However, it has been recommended
that non-inferiority trials, and possibly all RCTs, should
describe both ITTand PP results, and facilitate the reader’s
focus on the more conservative findings [4, 13, 19–22].
Results from this study suggested that about half of non-
inferiority trials of anti-infectives currently report both
ITT and PP. This is another opportunity for improvement
in transparency of study reporting that could yield more
clinically applicable results.
Having focused on infectious disease medications,
future studies could examine additional therapeutic
classifications, such as cardiovascular medications.
Additionally, subsequent work could focus on non-
inferiority trials on a more global scale. A recent cross-
sectional study of non-inferiority trials identified serious
shortcomings in terms of reporting and justifying non-
inferiority margins, and other information needed to
interpret non-inferiority [23]. A broader assessment of
non-inferiority trial reporting focused on data analysis
populations could identify additional concerns. Along
with a broader scope focusing on different populations,
a more longitudinal approach spanning more years
could also be constructed to evaluate not only the preva-
lence of the use of ITT over the years, but also how this
modification to the effect size of studies changes with
different approaches to RCTs.
Results from this study will be applicable for medical pro-
fessionals in health systems, especially those with a role in
antimicrobial stewardship or direct patient care. However,
it should be cautioned that the consistent use of ITT in this
sample may not be extrapolated to other subspecialties.
Similarly, the proportion of non-inferiority trials used in
infectious diseases is somewhat higher than expected in
other disciplines, which further limits generalizability to
other therapeutic areas [7, 24]. Another potential limitation
is that the search purposefully focused on identifying and
evaluating the most impactful infectious diseases RCTs
published in highly regarded journals, and these results
themselves may represent a “best case” scenario.
Results from this study highlight key information to
consider when evaluating study methods and results, and
a general lack of transparency in study reporting. Without
a thorough understanding of the types and appropriate-
ness of data being presented in a study, decisions about
the use of a medication for a patient or its addition to the
hospital formulary become dependent on the study
authors’ presentation and conclusions. Lack of transpar-
ency could contribute to misinterpretation of important
findings or use of an agent outside of its intended target
population. Furthermore, the important shortcomings
identified in this study will also be important for journal
editors and peer reviewers to consider when evaluating
RCTs, particularly those of anti-infectives, for publication.
Conclusions
RCTs of anti-infectives commonly employ ITT and
mITT populations for their primary analysis; however, a
substantial portion of studies did not clearly report the
population that was used. Most of these RCTs do not
describe how missing data were addressed. Non-
inferiority trials of anti-infectives do not consistently
employ both ITT and PP populations.
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